PMID- 29550845
OWN - NLM
STAT- MEDLINE
DCOM- 20180628
LR  - 20180628
IS  - 1790-5427 (Print)
IS  - 1790-5427 (Linking)
VI  - 21
IP  - 1
DP  - 2018 Jan-Apr
TI  - Correlations between dual-phase 18F-FDG uptake and clinicopathologic and 
      biological markers of breast cancer.
PG  - 35-42
LID - 10.1967/s002449910705 [doi]
AB  - OBJECTIVE: To assess the correlations between dual-phase fluorine-18 
      fluorodeoxyglucose ((18)F-FDG) uptake and clinicopathological and 
      immunohistochemical prognostic factors in patients with surgically resected 
      breast cancer. SUBJECTS AND METHODS: We retrospectively analyzed the cases of 105 
      patients. We calculated the maximum standardized uptake value (SUVmax) at 85min 
      (SUV1), SUVmax at 125min (SUV2) and the retention index [RI]. Spearman's rank 
      correlation test, the Kruskal-Wallis test and receiver operating characteristic 
      (ROC) analysis were performed to assess the association between (18)F-FDG uptake 
      and the clinicopathological and immunohistochemical factors: glucose 
      transporter-1 (Glut-1), estrogen receptor alpha (ERalpha), ERbeta, progesterone receptor 
      (PR), human epidermal growth factor 2 (Her2), mammalian target of rapamycin 
      (mTOR), and P70S6kinase (P70S6). RESULTS: The SUV1 and SUV2 values were 
      correlated with Glut-1, pathological tumor size, ERalpha negativity, and pathological 
      stage (all P values were <0.05), but not with mTOR, P70S6, ERbeta, PR, Her2 or other 
      factors. The SUV1 and SUV2 in the triple negative subtype were significantly 
      higher than those of the hormone receptor-positive subtype (P<0.05). The RI was 
      associated with pathological tumor size alone. In the ROC analysis of Glut-1, the 
      areas under the curve for SUV1 and SUV2 were significantly larger than that for 
      RI (SUV1, P=0.032, SUV2, P=0.022). CONCLUSION: Glucose transporter-1, estrogen 
      receptor alpha negativity and nuclear grade might affect the high (18)F-FDG 
      uptake in breast cancer. The SUVmax might be more useful than the RI for 
      predicting the Glut-1 expression and the aggressiveness of breast cancer.
FAU - Kaida, Hayato
AU  - Kaida H
AD  - Department of Radiology, Kindai University, Faculty of Medicine Ohnohigashi 
      377-2, Osakasayama City, Osaka, 589-8511, Japan. kaida@med.kindai.ac.jp.
FAU - Azuma, Koichi
AU  - Azuma K
FAU - Toh, Uhi
AU  - Toh U
FAU - Kawahara, Akihiko
AU  - Kawahara A
FAU - Sadashima, Eiji
AU  - Sadashima E
FAU - Hattori, Satoshi
AU  - Hattori S
FAU - Akiba, Jun
AU  - Akiba J
FAU - Tahara, Nobuhiro
AU  - Tahara N
FAU - Rominger, Axel
AU  - Rominger A
FAU - Ishii, Kazunai
AU  - Ishii K
FAU - Murakami, Takamichi
AU  - Murakami T
FAU - Ishibashi, Masatoshi
AU  - Ishibashi M
LA  - eng
PT  - Journal Article
DEP - 20180320
PL  - Greece
TA  - Hell J Nucl Med
JT  - Hellenic journal of nuclear medicine
JID - 101257471
RN  - 0 (Biomarkers, Tumor)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biological Transport
MH  - Biomarkers, Tumor/*metabolism
MH  - Breast Neoplasms/diagnostic imaging/*metabolism/pathology
MH  - Female
MH  - Fluorodeoxyglucose F18/*metabolism
MH  - Humans
MH  - Middle Aged
MH  - Positron Emission Tomography Computed Tomography
MH  - ROC Curve
MH  - Retrospective Studies
EDAT- 2018/03/20 06:00
MHDA- 2018/06/29 06:00
CRDT- 2018/03/19 06:00
PHST- 2018/03/12 00:00 [received]
PHST- 2018/03/21 00:00 [accepted]
PHST- 2018/03/20 06:00 [pubmed]
PHST- 2018/06/29 06:00 [medline]
PHST- 2018/03/19 06:00 [entrez]
AID - s002449910705 [pii]
AID - 10.1967/s002449910705 [doi]
PST - ppublish
SO  - Hell J Nucl Med. 2018 Jan-Apr;21(1):35-42. doi: 10.1967/s002449910705. Epub 2018 
      Mar 20.